JP2017527275A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527275A5 JP2017527275A5 JP2017504173A JP2017504173A JP2017527275A5 JP 2017527275 A5 JP2017527275 A5 JP 2017527275A5 JP 2017504173 A JP2017504173 A JP 2017504173A JP 2017504173 A JP2017504173 A JP 2017504173A JP 2017527275 A5 JP2017527275 A5 JP 2017527275A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- car
- ror1
- ntrkr1
- antigen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 210000002865 immune cell Anatomy 0.000 claims description 12
- 108020001756 ligand binding domains Proteins 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 47
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 43
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 43
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims 4
- 210000004896 polypeptide structure Anatomy 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 3
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000034951 Genetic Translocation Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940124589 immunosuppressive drug Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 102000009490 IgG Receptors Human genes 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201470465 | 2014-07-29 | ||
| DKPA201470465 | 2014-07-29 | ||
| PCT/EP2015/067444 WO2016016344A1 (en) | 2014-07-29 | 2015-07-29 | Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527275A JP2017527275A (ja) | 2017-09-21 |
| JP2017527275A5 true JP2017527275A5 (cg-RX-API-DMAC7.html) | 2019-05-30 |
| JP6721568B2 JP6721568B2 (ja) | 2020-07-15 |
Family
ID=51300484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504173A Active JP6721568B2 (ja) | 2014-07-29 | 2015-07-29 | がん免疫療法のためのｒｏｒ１（ｎｔｒｋｒ１）特異的キメラ抗原レセプター |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10752684B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3174557B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6721568B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102048855B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106922148B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015295349B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017001821A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2950381C (cg-RX-API-DMAC7.html) |
| DK (2) | DK3453406T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA034081B1 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2715413T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL250161B (cg-RX-API-DMAC7.html) |
| MX (1) | MX367787B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016016344A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| CA2956482A1 (en) | 2014-07-31 | 2016-02-04 | Cellectis | Ror1 specific multi-chain chimeric antigen receptor |
| DK3189073T4 (da) | 2014-09-04 | 2025-08-18 | Cellectis | Trofoblastglykoprotein (5t4, tpbg)-specifikke kimære antigenreceptorer til cancerimmunterapi |
| US20160208018A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| CN114634943A (zh) | 2015-05-18 | 2022-06-17 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| US10752670B2 (en) | 2015-05-20 | 2020-08-25 | Cellectis | Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy |
| AU2016345681A1 (en) | 2015-10-30 | 2018-05-10 | Nbe-Therapeutics Ag | Anti-ROR1 antibodies |
| UA125718C2 (uk) | 2016-01-20 | 2022-05-25 | Зе Скріппс Ресеарч Інстітьют | Композиції антитіл до ror1 і пов'язані з ними способи |
| AU2017213844A1 (en) | 2016-02-02 | 2018-08-02 | Fred Hutchinson Cancer Center | Anti-ROR1 antibodies and uses thereof |
| WO2017142928A1 (en) * | 2016-02-17 | 2017-08-24 | Macrogenics, Inc. | Ror1-binding molecules, and methods of use thereof |
| WO2017156479A1 (en) * | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Ror1 chimeric antigen receptors |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| IL261713B2 (en) * | 2016-03-19 | 2023-09-01 | F1 Oncology Inc | Methods and preparations for the transfer of lymphocytes and their regulated expansion |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CN105924533B (zh) * | 2016-07-13 | 2020-04-21 | 北京康爱瑞浩生物科技股份有限公司 | Ror1特异性嵌合抗原受体及其应用 |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| GB2564823B8 (en) | 2016-10-07 | 2022-06-29 | Tcr2 Therapeutics Inc | Compositions and methods for TCR reprogramming using fusion proteins |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN108276493B (zh) * | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| JP7254710B2 (ja) * | 2017-03-16 | 2023-04-10 | ザ ジェネラル ホスピタル コーポレイション | Ｃｄ３７を標的にするキメラ抗原受容体 |
| CA3056942A1 (en) * | 2017-03-29 | 2018-10-04 | Sunnybrook Research Institute | Engineered t-cell modulating molecules and methods of using same |
| CA3061546C (en) | 2017-04-28 | 2023-09-19 | Julius-Maximilians-Universitat Wurzburg | Ror1-specific chimeric antigen receptors (car) with humanized targeting domains |
| GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| BR112020001207A2 (pt) | 2017-07-20 | 2020-09-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | composições e métodos para atingir cânceres expressando cd33 |
| KR102486090B1 (ko) | 2017-08-07 | 2023-01-10 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
| WO2019051135A1 (en) * | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | METHODS FOR IMPROVING ADOPTIVE CELL THERAPY |
| CN107557337B (zh) * | 2017-09-15 | 2020-06-26 | 山东兴瑞生物科技有限公司 | 一种抗ror1安全型嵌合抗原受体修饰的免疫细胞及其应用 |
| US10428141B2 (en) * | 2017-11-03 | 2019-10-01 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-ROR1 immunotherapy |
| GB201719169D0 (en) * | 2017-11-20 | 2018-01-03 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor and ligand |
| CN109836498A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向ror1的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| CN108707619B (zh) * | 2018-05-28 | 2023-07-18 | 上海恒润达生生物科技股份有限公司 | 靶向ror1的嵌合抗原受体及其用途 |
| CN108441505B (zh) * | 2018-05-28 | 2023-07-07 | 上海恒润达生生物科技股份有限公司 | 一种靶向ror1的嵌合抗原受体及其用途 |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CA3105816A1 (en) | 2018-07-10 | 2020-01-16 | Precigen, Inc. | Ror-1 specific chimeric antigen receptors and uses thereof |
| WO2020018964A1 (en) * | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| US20240165232A1 (en) * | 2018-09-24 | 2024-05-23 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| US12227551B2 (en) | 2018-12-11 | 2025-02-18 | Obsidian Therapeutics, Inc. | Membrane bound IL12 compositions and methods for tunable regulation |
| MA54863A (fr) * | 2019-01-29 | 2021-12-08 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques du récepteur orphelin-1 de type récepteur à tyrosine kinase (ror1) |
| CA3132840A1 (en) | 2019-03-08 | 2020-09-17 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
| CA3134465A1 (en) * | 2019-03-26 | 2020-10-01 | The Regents Of The University Of California | Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers |
| CN111286512A (zh) * | 2019-06-05 | 2020-06-16 | 南京艾德免疫治疗研究院有限公司 | 靶向人源化酪氨酸激酶孤儿受体1的嵌合抗原受体及其用途 |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| CN114450308A (zh) | 2019-06-12 | 2022-05-06 | 黑曜石疗法公司 | 用于调节性调控的ca2组合物和方法 |
| US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| US11918649B2 (en) | 2019-09-18 | 2024-03-05 | Molecular Templates, Inc. | PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds |
| US12497453B2 (en) | 2019-09-27 | 2025-12-16 | Nanjing Immunophage Biotech Co., Ltd. | ROR1 specific chimeric antigen receptors and their therapeutic applications |
| CN110643574A (zh) * | 2019-10-30 | 2020-01-03 | 西南医科大学 | 用于肿瘤浸润性淋巴细胞快速培养的饲养细胞的制备方法 |
| WO2021216691A1 (en) * | 2020-04-21 | 2021-10-28 | Croce Carlo M | Methods of detecting and treating cancers characterized by loss of mir15 and mir16 expression |
| WO2021231655A1 (en) * | 2020-05-12 | 2021-11-18 | Lyell Immunopharma, Inc. | Chimeric antigen receptor spacers |
| EP4262858A1 (en) * | 2020-12-16 | 2023-10-25 | Molecular Templates, Inc. | Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| CN116940378A (zh) * | 2021-02-01 | 2023-10-24 | 加利福尼亚大学董事会 | 神经内分泌癌的治疗 |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| KR102671408B1 (ko) | 2021-02-26 | 2024-06-04 | 진화섭 | HLA class II에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 |
| CN114539411B (zh) * | 2022-04-29 | 2022-11-11 | 山东博安生物技术股份有限公司 | 一种ror1抗体或其抗原结合片段 |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024213040A1 (zh) * | 2023-04-11 | 2024-10-17 | 浙江博锐生物制药有限公司 | 抗ror1抗体及其药物偶联物 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU2001243288B2 (en) | 2000-02-24 | 2005-11-24 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| CA2427858A1 (en) | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| WO2004083379A2 (en) | 2003-03-14 | 2004-09-30 | Walters Richard E | Large volume ex vivo electroporation method |
| CA2536238C (en) | 2003-08-18 | 2015-04-07 | Medimmune, Inc. | Humanization of antibodies |
| WO2005035575A2 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| KR101030612B1 (ko) * | 2005-10-21 | 2011-04-20 | 에프. 호프만-라 로슈 아게 | 폴리펩타이드의 재조합 발현 방법 |
| SG170091A1 (en) | 2006-03-10 | 2011-04-29 | Wyeth Corp | Anti-5t4 antibodies and uses thereof |
| EP2435067A2 (en) * | 2009-05-28 | 2012-04-04 | Glaxo Group Limited | Stem cell targeting |
| WO2012012695A2 (en) | 2010-07-23 | 2012-01-26 | Fred Hutchinson Cancer Research Center | A method for the treatment of obesity |
| EP2614151B1 (en) * | 2010-09-08 | 2019-07-24 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| PT2663579T (pt) | 2011-01-14 | 2017-07-28 | Univ California | Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização |
| BR112013024395B1 (pt) | 2011-03-23 | 2021-10-26 | Fred Hutchinson Cancer Research Center | Composições adotivas de imunoterapia celular e método para fabricação da dita composição |
| EP3320910A1 (en) | 2011-04-05 | 2018-05-16 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| US9708384B2 (en) * | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
| RU2644243C2 (ru) * | 2011-10-20 | 2018-02-08 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы к cd22 |
| US9272002B2 (en) * | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| EP2836239A1 (en) * | 2012-04-11 | 2015-02-18 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| EP2855666B1 (en) | 2012-05-25 | 2019-12-04 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| SMT202100005T1 (it) | 2012-08-20 | 2021-05-07 | Hutchinson Fred Cancer Res | Metodo e composizioni per immunoterapia cellulare |
| DK3489261T3 (da) | 2012-08-24 | 2020-12-14 | Univ California | Antistoffer og vacciner til anvendelse ved behandling af ror1-cancere og hæmning af metastase |
| AU2013312838B2 (en) * | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
-
2015
- 2015-07-29 WO PCT/EP2015/067444 patent/WO2016016344A1/en not_active Ceased
- 2015-07-29 ES ES15744216T patent/ES2715413T3/es active Active
- 2015-07-29 JP JP2017504173A patent/JP6721568B2/ja active Active
- 2015-07-29 EP EP15744216.1A patent/EP3174557B1/en active Active
- 2015-07-29 ES ES18199948T patent/ES2876925T3/es active Active
- 2015-07-29 AU AU2015295349A patent/AU2015295349B2/en active Active
- 2015-07-29 KR KR1020177005614A patent/KR102048855B1/ko active Active
- 2015-07-29 DK DK18199948.3T patent/DK3453406T3/da active
- 2015-07-29 DK DK15744216.1T patent/DK3174557T3/en active
- 2015-07-29 MX MX2017001211A patent/MX367787B/es active IP Right Grant
- 2015-07-29 BR BR112017001821A patent/BR112017001821A2/pt not_active Application Discontinuation
- 2015-07-29 EA EA201790280A patent/EA034081B1/ru not_active IP Right Cessation
- 2015-07-29 CA CA2950381A patent/CA2950381C/en active Active
- 2015-07-29 CN CN201580052319.1A patent/CN106922148B/zh active Active
- 2015-07-29 EP EP18199948.3A patent/EP3453406B1/en active Active
- 2015-07-29 US US15/329,932 patent/US10752684B2/en active Active
-
2017
- 2017-01-17 IL IL250161A patent/IL250161B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527275A5 (cg-RX-API-DMAC7.html) | ||
| TWI883026B (zh) | 抗ｄｌｌ３嵌合抗原受體及其用途 | |
| JP2017522893A5 (cg-RX-API-DMAC7.html) | ||
| JP2024125370A (ja) | クローディン１８．２結合部分およびその利用 | |
| JP2022105558A (ja) | 新規のポリペプチド | |
| KR101605421B1 (ko) | B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도 | |
| JP2015527070A5 (cg-RX-API-DMAC7.html) | ||
| CN111971053A (zh) | 靶向肿瘤微环境的嵌合抗原受体 | |
| CN113993893A (zh) | 新cd40结合抗体 | |
| RS59373B1 (sr) | Vezujući molekuli za bcma i cd3 | |
| CN110709421A (zh) | 针对ox40和ctla-4的双特异性抗体 | |
| CN107428835A (zh) | 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体 | |
| JP2018503380A5 (cg-RX-API-DMAC7.html) | ||
| CN112074278A (zh) | Bcma-car-t细胞 | |
| JP2023550998A (ja) | Ｃｌｄｎ１８．２抗体及びその使用 | |
| CA3227227A1 (en) | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 | |
| CN115279792B (zh) | 对bcma特异的抗体及嵌合抗原受体 | |
| US20230192861A1 (en) | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof | |
| US20230235064A1 (en) | Bispecific immune cell engagers with binding specificity for hla-g and another antigen | |
| CA3240254A1 (en) | Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors | |
| CN115151572B (zh) | 针对ror1的抗体及其用途 | |
| JP2023535485A (ja) | 抗ｃｄ２２シングルドメイン抗体および治療用コンストラクト | |
| JPWO2020247618A5 (cg-RX-API-DMAC7.html) | ||
| Matus | Development of Bispecific Proteins for Applications in Immunotherapy | |
| WO2025251924A1 (zh) | 特异性结合cd3/tcr复合物的纳米抗体或其抗原结合片段及其应用 |